Titre :
  • Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Auteur : Stupp, R ; Mason, Warren P ; van den Bent, M J ; Weller, M ; Fisher, Barbara ; Taphoorn, M J B ; Belanger, Karl ; Brandes, Alba A ; Marosi, C ; Bogdahn, Ulrich ; Curschmann, Jürgen ; Janzer, Robert C ; Ludwin, Samuel K ; Gorlia, Thierry ; Allgeier, Anouk ; Lacombe, Denis ; Cairncross, J G ; Eisenhauer, Elizabeth ; Mirimanoff, René Olivier ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups ; National Cancer Institute of Canada Clinical Trials Group
Informations sur la publication : The New England journal of medicine, 352, 10, (page 987-996)
Statut de publication : Publié, 2005-03
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adrenal Cortex Hormones -- therapeutic use
Adult
Aged
Antineoplastic Agents, Alkylating -- adverse effects
Antineoplastic Agents, Alkylating -- therapeutic use
Brain Neoplasms -- drug therapy
Brain Neoplasms -- mortality
Brain Neoplasms -- radiotherapy
Chemotherapy, Adjuvant
Dacarbazine -- adverse effects
Dacarbazine -- analogs & derivatives
Dacarbazine -- therapeutic use
Disease Progression
Female
Glioblastoma -- drug therapy
Glioblastoma -- mortality
Glioblastoma -- radiotherapy
Humans
Male
Middle Aged
Proportional Hazards Models
Radiotherapy, Computer-Assisted -- adverse effects
Survival Analysis
Note : Clinical Trial
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langue :
  • Anglais
Identificateurs : urn:issn:0028-4793 
info:doi/10.1056/NEJMoa043330
info:pii/352/10/987
info:pmid/15758009